Cansino Biologics (06185): Manhisin® drug supplement application accepted

Zhitong Financial App News, Cansino Biotech (06185) announced that the company has obtained the “Notice of Acceptance” issued by the China National Drug Administration (CNDA). According to the notice, the State Drug Administration has accepted a supplementary application to expand the applicable age range of the company's ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier) (MCV4, trade name: Manhisin®) from 3 months to 6 years (83 years old).

Our company's MANHEXIN® is the first meningococcal quadrivalent conjugate vaccine product in China. It was approved for marketing in December 2021, and the applicable age range was extended to children aged 3 months to 6 (83 months) in February 2026. Its launch has narrowed the gap between China and developed countries in this field, filled the gap in China's lack of high-end vaccines in this field, and provided a better solution for preventing encephalitis in children aged 6 and under in China. With its innovative advantages, MENHYXIN® has shown strong market performance and achieved a continuous rise in market share.